Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2020 | The cell therapy landscape: disruptive technologies

Helen Tayton-Martin • 15 Oct 2020
Meeting on the Mesa 2020
General

Helen Tayton-Martin, PhD, Adaptimmune, Oxford, UK, discusses disruptive technologies that may change the cell therapy landscape. Specifically discussed is the formation of an off-the-shelf T-cell product able to treat solid tumors with the same potency and efficacy seen with current cellular therapies. This interview took place during the 2020 Meeting on the Mesa congress.

More from Helen Tayton-Martin

6:02
Adaptimmune: SPEAR T-cells
Helen Tayton-Martin • 15 Oct 2020
4:21
T-cells: challenges in bringing to market
Helen Tayton-Martin • 15 Oct 2020
1:41
The potential of RegenMed in the oncology space
Helen Tayton-Martin • 15 Oct 2020

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
2:08
Streamlining cell therapy manufacturing with CliniMACS Prodigy
Saskia Rösch • 6 Apr 2022
The content of VJRegenMed is intended for healthcare professionals